Volume | 127,008 |
|
|||||
News | - | ||||||
Day High | 19.48 | Low High |
|||||
Day Low | 17.89 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
LENZ Therapeutics Inc | LENZ | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
17.89 | 17.89 | 19.48 | 18.54 | 18.63 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
4,047 | 127,008 | $ 18.51 | $ 2,351,537 | - | 14.42 - 24.59 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:31:14 | 71 | $ 18.00 | USD |
LENZ Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
474.17M | 25.53M | - | 0 | -124.65M | -4.88 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
LENZ Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LENZ Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 15.04 | 19.98 | 14.9201 | 18.20 | 180,806 | 3.50 | 23.27% |
1 Month | 16.50 | 19.98 | 14.42 | 16.63 | 180,937 | 2.04 | 12.36% |
3 Months | 15.98 | 24.59 | 14.42 | 17.23 | 159,903 | 2.56 | 16.02% |
6 Months | 15.98 | 24.59 | 14.42 | 17.23 | 159,903 | 2.56 | 16.02% |
1 Year | 15.98 | 24.59 | 14.42 | 17.23 | 159,903 | 2.56 | 16.02% |
3 Years | 15.98 | 24.59 | 14.42 | 17.23 | 159,903 | 2.56 | 16.02% |
5 Years | 15.98 | 24.59 | 14.42 | 17.23 | 159,903 | 2.56 | 16.02% |
LENZ Therapeutics Description
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States. |